Inavolisib was developed by which pharmaceutical company

The research and development of Inavolisib was completed by GENENTECH INC, a company affiliated with Roche, the world's leading biopharmaceutical group, and one of the most important innovation drivers in the field of oncology. As a pioneer in molecularly targeted drug research, Genentech has profound technological accumulation in precision therapy, antibody engineering and tumor signaling pathway research, laying a scientific foundation for the birth of Inarisep.

The core of the design of inaliset is to achieve highly selective inhibition of PI3Kα isoform. The PI3K pathway is one of the most common drivers of breast cancer, and PIK3CA mutations are one of the best-studied targets in breast cancer biology. Through in-depth research on the signaling mechanism of cancer cells, Genentech has developed a series of inhibitors that precisely target specific subtypes, and inaliside is a representative innovative drug developed in this system.

Compared with traditional PI3K inhibitors, inalise has a clearer research and development goal, which is to improve selectivity on the basis of reducing toxicity, so that patients can obtain better tolerance and continuous treatment opportunities. Genentech uses a multi-dimensional screening method in the drug design process to enable the drug to bind to mutant PI3Kα more stably and accurately in the body, thereby reducing non-specific effects on other isoforms. For this reason, Inaliseis regarded as a new generation of PI3Kα-targeted drugs and is expected to become an important part of the future precision treatment of breast cancer.

Roche has long been a leader in the field of HER2-positive and related mutation breast cancer. From trastuzumab and pertuzumab to T-DM1, T-DXd, and now inalisate, its product line has built a relatively complete HER2-related treatment system. The addition of inalisemeans that the company has once again completed key targets in the breast cancer drug matrix, providing new therapeutic tools for PIK3CA mutations, a subgroup with a high incidence.

Reference materials:https://www.itovebi-hcp.com/